329.48

0.41% -1.2876

Insulet Corporation (PODD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PODD Giù? Forum Previsione

Precedente Chiudi:

$330.77

Aprire:

$329.88

Volume 24 ore:

56,669

Relative Volume:

0.08

Capitalizzazione di mercato:

$23.20B

Reddito:

$2.36B

Utile/perdita netta:

$236.10M

Rapporto P/E:

100.15

EPS:

3.29

Flusso di cassa netto:

$382.50M

1 W Prestazione:

+1.96%

1M Prestazione:

+13.50%

6M Prestazione:

+23.52%

1 anno Prestazione:

+78.02%

Intervallo 1D:

$327.89

$330.76

Intervallo di 1 settimana:

$322.85

$334.18

Portata 52W:

$180.31

$334.18

Insulet Corporation Stock (PODD) Company Profile

Nome

Insulet Corporation

Settore

Healthcare (1158)

Industria

Medical Devices (150)

Telefono

978-600-7000

Indirizzo

100 NAGOG PARK, ACTON, MA

Dipendente

3,900

Cinguettio

@insulet_uk

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PODD's Discussions on Twitter

Confronta PODD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PODD Insulet Corporation	329.52	22.74B	2.36B	236.10M	382.50M	3.29
ABT Abbott Laboratories	131.50	226.73B	43.11B	13.94B	6.78B	7.98
BSX Boston Scientific Corp	105.56	152.69B	18.49B	2.50B	3.49B	1.68
SYK Stryker Corp	390.89	145.89B	23.82B	2.92B	4.02B	7.55
MDT Medtronic Plc	92.20	118.91B	33.54B	4.69B	5.19B	3.62
EW Edwards Lifesciences Corp	81.75	45.97B	5.69B	1.41B	577.90M	6.95

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-16	Iniziato	Truist	Buy
2025-05-30	Iniziato	Goldman	Buy
2025-05-13	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-04-29	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-03-06	Iniziato	RBC Capital Mkts	Outperform
2024-11-06	Iniziato	Bernstein	Outperform
2024-05-30	Iniziato	Redburn Atlantic	Buy
2024-05-07	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2023-12-21	Aggiornamento	Robert W. Baird	Neutral → Outperform
2023-12-04	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-10-02	Aggiornamento	Jefferies	Hold → Buy
2023-08-21	Aggiornamento	Citigroup	Neutral → Buy
2023-08-21	Downgrade	Robert W. Baird	Outperform → Neutral
2023-05-30	Ripresa	Morgan Stanley	Equal-Weight
2023-01-26	Iniziato	Wolfe Research	Peer Perform
2022-11-04	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-18	Iniziato	Barclays	Equal Weight
2022-10-12	Iniziato	Jefferies	Hold
2022-07-11	Downgrade	Citigroup	Buy → Neutral
2022-03-02	Ripresa	BofA Securities	Buy
2022-02-03	Aggiornamento	BTIG Research	Neutral → Buy
2022-02-02	Aggiornamento	UBS	Neutral → Buy
2022-01-31	Aggiornamento	Oppenheimer	Perform → Outperform
2021-07-21	Ripresa	Cowen	Outperform
2021-05-25	Iniziato	Barclays	Overweight
2021-04-01	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-03-19	Aggiornamento	Canaccord Genuity	Hold → Buy
2021-01-29	Downgrade	Piper Sandler	Overweight → Neutral
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-07-28	Iniziato	Wells Fargo	Overweight
2020-04-24	Downgrade	SVB Leerink	Outperform → Mkt Perform
2020-04-03	Iniziato	BofA/Merrill	Neutral
2020-03-31	Downgrade	Berenberg	Buy → Hold
2020-03-05	Iniziato	Citigroup	Buy
2019-12-10	Iniziato	CFRA	Sell
2019-10-23	Iniziato	Stifel	Hold
2019-10-18	Downgrade	Canaccord Genuity	Buy → Hold
2019-10-14	Downgrade	BTIG Research	Buy → Neutral
2019-10-04	Downgrade	UBS	Buy → Neutral
2019-10-03	Downgrade	Guggenheim	Buy → Neutral
2019-08-06	Aggiornamento	JP Morgan	Neutral → Overweight
2019-06-10	Downgrade	Northland Capital	Outperform → Market Perform
2019-05-06	Aggiornamento	BTIG Research	Neutral → Buy
2018-04-20	Iniziato	Berenberg	Buy
2018-02-22	Reiterato	Barclays	Overweight
2018-01-08	Aggiornamento	Raymond James	Mkt Perform → Outperform
2017-11-03	Aggiornamento	Canaccord Genuity	Hold → Buy
2017-09-15	Iniziato	Barclays	Overweight

Mostra tutto

Insulet Corporation Borsa (PODD) Ultime notizie

Aug 20, 2025

No. 1 Medical Device Maker Insulet In 11 Stocks New To IBD Lists - Investor's Business Daily

Aug 20, 2025

Insulet stock hits 52-week high at $329.55 - Investing.com

Aug 20, 2025

Cisco, Rocket Companies, Insulet And More On CNBC's 'Final Trades' - Benzinga

Aug 20, 2025

Aug 19, 2025

Insulet Corp to Present at Upcoming Investor Conferences Amidst Diabetes Management Focus - AInvest

Aug 19, 2025

Why This IBD Stock Of The Day Just Broke Out — Again - Investor's Business Daily

Aug 19, 2025

Is Insulet Corporation subject to activist investor interest2025 Market WrapUp & AI Powered Trade Plan Recommendations - thegnnews.com

Aug 16, 2025

Insulet’s (PODD) Aggressive Revenue Guidance and Buyback Might Change the Case for Investing - simplywall.st

Aug 16, 2025

Aug 15, 2025

Published on: 2025-08-16 12:18:14 - sundaytimes.kr

Aug 15, 2025

Insulet Shares Soar on Volume Surge as Stock Ranks 495th in Market Activity for the Day - AInvest

Aug 15, 2025

Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Catalysts & High Accuracy Trade Signal Alerts - newsyoung.net

Aug 15, 2025

Aug 14, 2025

Short Covering May Lift Insulet Corporation in Near TermQuarterly Profit Review & Weekly High Return Opportunities - sundaytimes.kr

Aug 14, 2025

Stock Market Today: Indexes Hold Strong, But Small Caps Lag; Netflix, Amazon, Insulet In Focus - Investor's Business Daily

Aug 14, 2025

There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings - simplywall.st

Aug 14, 2025

Insulet's (NASDAQ:PODD) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance

Aug 14, 2025

Investors Can Find Comfort In Insulet's (NASDAQ:PODD) Earnings Quality - 富途牛牛

Aug 14, 2025

The Top 5 Analyst Questions From Insulet’s Q2 Earnings Call - Yahoo Finance

Aug 14, 2025

Aug 13, 2025

Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD) - Seeking Alpha

Aug 13, 2025

Elliott Wave Theory Predicts Pullback in Insulet CorporationEarnings Miss & Intraday High Probability Setup Alerts - beatles.ru

Aug 13, 2025

Sapiens International Q2 Earnings Decline, Revenue Rises Amid Acquisition Deal - AInvest

Aug 13, 2025

PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - Yahoo Finance

Aug 13, 2025

Aug 12, 2025

Insulet Rises to 470th in Trading Volume as Q2 Revenue Surges 32.9 and Margins Expand - AInvest

Aug 12, 2025

Insulet Q2 Earnings and Revenue Exceed Estimates, Stock Rises, Margins Improve - AInvest

Aug 12, 2025

Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - TradingView

Aug 12, 2025

Insulet Corporation Reports Strong Q2 2025 Growth - MSN

Aug 12, 2025

Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com

Aug 12, 2025

Aug 11, 2025

Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest

Aug 11, 2025

Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st

Aug 11, 2025

Aug 10, 2025

Is It Too Late to Sell Insulet CorporationLow Drawdown Real Time Trading Tips Shared - beatles.ru

Aug 10, 2025

Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru

Aug 10, 2025

Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN

Aug 10, 2025

Aug 09, 2025

Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest

Aug 09, 2025

Aug 08, 2025

Insulet’s Earnings Call Highlights Robust Growth and Optimism - The Globe and Mail

Aug 08, 2025

Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛

Aug 08, 2025

RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest

Aug 08, 2025

Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest

Aug 08, 2025

Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st

Aug 08, 2025

Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener

Aug 08, 2025

Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada

Aug 08, 2025

Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria

Aug 08, 2025

RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener

Aug 08, 2025

Insulet price target raised to $350 from $330 at RBC Capital - TipRanks

Aug 08, 2025